Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stake Raised by Creative Planning

Creative Planning increased its holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 25.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,884 shares of the company’s stock after buying an additional 6,933 shares during the quarter. Creative Planning owned about 0.06% of Phathom Pharmaceuticals worth $613,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company lifted its stake in shares of Phathom Pharmaceuticals by 10.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company’s stock worth $144,000 after acquiring an additional 1,339 shares during the period. Inspirion Wealth Advisors LLC lifted its position in Phathom Pharmaceuticals by 4.3% in the second quarter. Inspirion Wealth Advisors LLC now owns 36,634 shares of the company’s stock worth $377,000 after purchasing an additional 1,500 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Phathom Pharmaceuticals by 12.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,573 shares of the company’s stock valued at $208,000 after purchasing an additional 2,172 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Phathom Pharmaceuticals by 42.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,071 shares of the company’s stock valued at $104,000 after purchasing an additional 2,987 shares during the period. Finally, Rhumbline Advisers raised its stake in shares of Phathom Pharmaceuticals by 17.1% in the 2nd quarter. Rhumbline Advisers now owns 55,178 shares of the company’s stock worth $568,000 after buying an additional 8,075 shares in the last quarter. 99.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently commented on PHAT shares. The Goldman Sachs Group boosted their target price on shares of Phathom Pharmaceuticals from $10.00 to $12.00 and gave the stock a “neutral” rating in a report on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Monday, August 12th. Finally, Needham & Company LLC reissued a “buy” rating and set a $26.00 price objective on shares of Phathom Pharmaceuticals in a research note on Friday, September 13th.

Phathom Pharmaceuticals Price Performance

Shares of PHAT opened at $18.94 on Tuesday. Phathom Pharmaceuticals, Inc. has a one year low of $6.07 and a one year high of $19.71. The company has a market capitalization of $1.13 billion, a P/E ratio of -3.69 and a beta of 0.72. The business’s 50 day simple moving average is $17.14 and its 200-day simple moving average is $13.10.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($1.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.39) by $0.04. The firm had revenue of $7.32 million during the quarter, compared to analyst estimates of $5.65 million. On average, sell-side analysts anticipate that Phathom Pharmaceuticals, Inc. will post -6.03 EPS for the current fiscal year.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.